DiscoverNewsRamp Science, Exploration and Discovery PodcastExploring Next-Generation Treatment for Major Depressive Disorder with Alzamend Neuro, Inc.
Exploring Next-Generation Treatment for Major Depressive Disorder with Alzamend Neuro, Inc.

Exploring Next-Generation Treatment for Major Depressive Disorder with Alzamend Neuro, Inc.

Update: 2024-08-12
Share

Description

Join us as we discuss Alzamend Neuro, Inc.'s partnership with Massachusetts General Hospital for a Phase II trial of a next-generation treatment for Major Depressive Disorder (MDD). Learn about the innovative approach of using AL001, a lithium-based therapeutic candidate, to address the symptoms of MDD. CEO Stephan Jackman shares his optimism for the potential of AL001 as a safer and more effective alternative for MDD treatment. Alzamend Neuro is also actively involved in Phase II trials for bipolar disorder and Alzheimer's disease, with Dr. Ovidiu Andronesi leading the way.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Exploring Next-Generation Treatment for Major Depressive Disorder with Alzamend Neuro, Inc.

Exploring Next-Generation Treatment for Major Depressive Disorder with Alzamend Neuro, Inc.

NewsRamp